Topic: Eli Lilly and Company

Dense Breasts + Hormones Up Cancer Risk After Menopause

Modern Medicine - 565 days ago
Postmenopausal women with high breast density, especially those undergoing hormone therapy with estrogen plus progestin, are at higher risk for developing breast cancer, according to a study published online July 19 in the Journal of Clinical Oncology.. The researchers used a survival ...

Lilly will not seek FDA approval for arzoxifene

AP Features - 900 days ago
Eli Lilly & Co. said Tuesday it will not seek Food and Drug Administration approval for its developing postmenopausal osteoporosis drug because of certain study results and safety concerns.The company said the drug met its late-stage study goals of reducing the risk ...
Read More...

Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density

Drugs.com - 1032 days ago
INDIANAPOLIS, April 8, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Phase III data, published online this week in the Journal of Clinical Endocrinology & Metabolism, showed that arzoxifene, an investigational selective estrogen receptor modulator (SERM) being developed by Eli Lilly and Company ...